



Original Research

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments



L. Kandolf Sekulovic^{a,*}, K. Peris^b, A. Hauschild^c, A. Stratigos^d, J.-J. Grob^e, P. Nathan^f, R. Dummer^g, A.-M. Forsea^h, C. Hoellerⁱ, H. Gogas^d, L. Demidov^j, C. Lebbe^k, C. Blank^l, J. Olah^m, L. Bastholtⁿ, D. Herceg^o, B. Neyns^p, R. Vieira^q, J. Hansson^r, P. Rutkowski^s, I. Krajsova^t, M. Bylaite-Bucinskiene^u, I. Zalaudek^v, J. Maric-Brozic^w, N. Babovic^x, M. Banjin^y, K. Putnik^z, G. Weinlich^{aa}, V. Todorovic^{ab}, K. Kirov^{ac}, J. Ocvirk^{ad}, A. Zhukavets^{ae}, M. Kukushkina^{af}, L. De La Cruz Merino^{ag}, A. Ymeri^{ah}, M. Risteski^{ai}, C. Garbe^{aj}

^a Department of Dermatology, Medical Faculty, Military Medical Academy, Belgrade, Serbia

^b Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy

^c Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany

^d National and Kapodistrian University of Athens, Greece

^e Service de Dermatologie et Cancérologie Cutanée, Hôpital de la Timone, Marseille, France

^f Mount Vernon Cancer Centre, Northwood, United Kingdom

^g UniversitätsSpital Zürich-Skin Cancer Center, University Hospital, Zürich, Switzerland

^h Carol Davila University of Medicine and Pharmacy, Elias University Hospital Bucharest, Romania

ⁱ Department of Dermatology, Medical University of Vienna, Vienna, Austria

^j NN Blokhin Russian Cancer Research Center, Moscow, Russia

^k APHP Hospital Saint Louis, Paris, France

^l Netherland Cancer Institute, Amsterdam, Netherlands

^m Department of Dermatology and Allergology, University of Szeged, Hungary

ⁿ Department of Oncology, Odense University Hospital, Denmark

^o Department of Oncology, University Hospital Zagreb, Croatia

^p Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium

^q Department of Dermatology, Medical Faculty, University of Coimbra, Portugal

^r Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden

^s Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Poland

^t General Teaching Hospital, Prague, Czech Republic

^u Department of Dermatology, Vilnius University, Lithuania

^v Division of Dermatology and Venerology, Medical University of Graz, Graz, Austria

^w University Hospital Center Sestre Milosrdnice, Zagreb, Croatia

^x Institute of Oncology and Radiology of Serbia, Belgrade, Serbia

^y Department of Oncology, University Hospital Sarajevo, Bosnia and Herzegovina

^z North Estonia Medical Centre, Tallinn, Estonia

* Corresponding author.

^{aa} Department of Dermatology & Venerology & Allergy, Medical University Innsbruck, Austria

^{ab} Clinic for Oncology and Radiotherapy, Podgorica, Montenegro

^{ac} Clinic of Oncodermatology, National Cancer Center, Sofia, Bulgaria

^{ad} Institute of Oncology Ljubljana, Ljubljana, Slovenia

^{ae} N.N. Alexandrov National Cancer Center of Belarus (NCCB), Minsk, Belarus

^{af} National Cancer Institute, Kiev, Ukraine

^{ag} Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain

^{ah} University Hospital Mother Theresa, Tirana, Albania

^{ai} University Clinic of Radiotherapy and Oncology, Skopje, Former Yugoslav Republic of Macedonia

^{aj} Centre for Dermatoooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

Received 19 January 2017; accepted 21 January 2017

Available online 4 March 2017

KEYWORDS

Access;
Innovative medicines;
Metastatic melanoma;
Treatment;
Immunoncology;
Targeted therapy;
Health expenditure per capita;
Human development index

Abstract Background: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF).

Materials and methods: Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes.

Results: The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), ($r = 0.662$; $p < 0.001$), health expenditure per capita ($r = 0.695$; $p < 0.001$) and the Mackenbach score of health policy performance ($r = 0.765$; $p < 0.001$) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines.

Conclusions: Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increase the awareness of national and European policymakers, oncological societies, melanoma patients' associations and pharma industry.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

A tremendous breakthrough in the treatment of metastatic melanoma occurred in recent years with the targeted inhibition of RAF-MEK-ERK (i.e. the MAP kinase) pathway with the use of MAP kinase inhibitors on the one hand and immunotherapy using immune checkpoint inhibitors on the other that have an impressive effect on overall survival. Two-year survival rates have reached 50% with either anti-PD1 immunotherapy (immune checkpoint inhibitor) or the BRAF/MEK inhibitor combination (e.g. BRAF inhibitors, such as vemurafenib or dabrafenib and MEK inhibitors,

such as cobimetinib or trametenib) compared to <10% with chemotherapy [1–4]. Early clinical trials showed a dramatic improvement of 34% in 5-year survival rate for nivolumab as the first PD1-antibody tested in melanoma [2–4]. To date, the longest follow-up suggests a 3-year survival rate as high as 44% with both immunotherapy and combined targeted therapies. If patients have normal values of lactate dehydrogenase (LDH), a 3-year survival of up to 60% appears to be realistic [2–4].

These agents have become first-line recommended treatments by major international melanoma guidelines including those by the European Society of Medical Oncology (ESMO), the European Dermatology Forum

Download English Version:

<https://daneshyari.com/en/article/5526257>

Download Persian Version:

<https://daneshyari.com/article/5526257>

[Daneshyari.com](https://daneshyari.com)